Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP001: Endoscopic and histologic outcomes in patients with moderate-to-severe Ulcerative Colitis treated with infliximab: A post hoc analysis of the Phase 3 LIBERTY-UC studyECCO'25 Berlin
Year: 2025
Authors: Colombel, Jean-Frédéric
DOP002: Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)ECCO'25 Berlin
Year: 2025
Authors: Panaccione, Remo
DOP003: Cromoendoscopy versus second generation Narrow band Imaging for dysplasia detection in IBD. A prospective randomized controlled trial.ECCO'25 Berlin
Year: 2025
Authors: Martin Arranz, Eduardo
DOP004: Proactive fecal calprotectin testing in ulcerative colitis: Initial results of the PROMOTE UC studyECCO'25 Berlin
Year: 2025
Authors: Rosenfeld, Greg
DOP005: Long-term efficacy and safety of mirikizumab treatment for Crohn’s Disease: Results from the VIVID-2 open-label extension studyECCO'25 Berlin
Year: 2025
Authors: Vermeire, Séverine
DOP006: Long term maintenance treatment with vedolizumab in pediatric IBD: a three-year follow-up of the prospective multicenter VEDOKIDS studyECCO'25 Berlin
Year: 2025
Authors: Turner, Dan
DOP007: Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trialECCO'25 Berlin
Year: 2025
Authors: Jairath, Vipul
DOP008: High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional Study (EARLY CD)ECCO'25 Berlin
Year: 2025
Authors: Liu, Jing
DOP009: Effectiveness and Safety of Advanced Combination Treatment (ACT) in patients with refractory inflammatory bowel disease or concomitant immune mediated disease or extra-intestinal manifestations: A Multi-Center Canadian StudyECCO'25 Berlin
Year: 2025
Authors: Solitano, Virginia
DOP010: Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics studyECCO'25 Berlin
Year: 2025
Authors: Dreesen, Erwin
DOP011: Colectomy rates of newly diagnosed Finnish Ulcerative Colitis patients are decreasingECCO'25 Berlin
Year: 2025
Authors: Kontola, Kristi
DOP012: Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical studyECCO'25 Berlin
Year: 2025
Authors: Schreieck, Amelie
DOP013: Risk of immune mediated inflammatory diseases associated with anti-TNFs and ustekinumab in Crohn’s disease: a nationwide population-based cohort studyECCO'25 Berlin
Year: 2025
Authors: Kirchgesner, Julien
DOP014: Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension studyECCO'25 Berlin
Year: 2025
Authors: Atreya, Raja
DOP015: Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program.ECCO'25 Berlin
Year: 2025
Authors: Connor, Susan Jane
DOP016: Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term ExtensionECCO'25 Berlin
Year: 2025
Authors: Ferrante, Marc
DOP017: Infliximab induction fails to reach targets in Perianal Fistulizing Crohn’s Disease: first results from the ATLANTIC studyECCO'25 Berlin
Year: 2025
Authors: Mulders, Lieven
DOP018: Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programmeECCO'25 Berlin
Year: 2025
Authors: Vermeire, Séverine
DOP019: Reduced Gut Microbial Amino Acid Auxotrophies and Enhanced Tryptophan Degradation in Inflammatory Bowel DiseaseECCO'25 Berlin
Year: 2025
Authors: Waschina, Silvio
DOP020: Baseline Microbiota and Differences in Donor-Recipient Richness as Determinants of Fecal Microbiota Transplantation Efficacy in Ulcerative ColitisECCO'25 Berlin
Year: 2025
Authors: Deleu, Sara